Magpie Pharmaceuticals CO. LTD.
3:00 PM - 3:15 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
Guangzhou Magpie Pharmaceuticals, Inc. (MPI) is a clinical stage drug discovery and development company. MPI focuses on developing novel treatments for cerebro-cardiovascular, neurodegenerative, and mitochondrial dysfunction diseases, as well as diabetic kidney disease.
Robust pipeline of clinical stage assets: 7 new NCEs in development, 2 phase III, 6 phase II, and 1 phase I clinical stage assets in China, as well as 2 phase I-ready assets in the USA.
Potential first-in-class medicines for diabetic kidney disease, pulmonary arterial hypertension and Alzheimer’s disease with novel mechanisms of action, superior efficacy and an excellent safety profile.
Robust pipeline of clinical stage assets: 7 new NCEs in development, 2 phase III, 6 phase II, and 1 phase I clinical stage assets in China, as well as 2 phase I-ready assets in the USA.
Potential first-in-class medicines for diabetic kidney disease, pulmonary arterial hypertension and Alzheimer’s disease with novel mechanisms of action, superior efficacy and an excellent safety profile.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Guangdong Province
Company HQ Country:
China
Year Founded:
2011
Main Therapeutic Focus:
Other
Lead Product in Development:
Not Provided
Development Phase of Primary Product:
Not Provided
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
